PCSK9 targets important for lipid metabolism-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

PCSK9 targets important for lipid metabolism

Published:2017-02-07 Issue:S1 Volume:12 Page:2-11
ISSN:1861-0706
Container-title:Clinical Research in Cardiology Supplements
language:en
Short-container-title:Clin Res Cardiol Suppl

Author:

Schulz Rainer,Schlüter Klaus-Dieter

Publisher

Springer Science and Business Media LLC

Subject

Radiology Nuclear Medicine and imaging,Molecular Biology,General Medicine,Structural Biology

Link

http://link.springer.com/content/pdf/10.1007/s11789-017-0085-0.pdf

Reference105 articles.

1. Al-Mashhadi RH, Sorensen CB, Kragh PM, Christoffersen C, Mortensen MB, Tolbod LP, Thim T, Du Y, Li J, Liu Y, Moldt B, Schmidt M, Vajta G, Larsen T, Purup S, Bolund L, Nielsen LB, Callesen H, Falk E, Mikkelsen JG, Bentzon JF (2013) Familial hypercholesterolemia and atherosclerosis in cloned minipigs created by DNA transposition of a human PCSK9 gain-of-function mutant. Sci Transl Med 5:166ra1. doi: 10.1126/scitranslmed.3004853

2. Argraves KM, Kozarsky KF, Fallon JT, Harpel PC, Strickland DK (1997) The atherogenic lipoprotein Lp(a) is internalized and degraded in a process mediated by the VLDL receptor. J Clin Invest 100:2170–2181

3. Benjannet S, Rhainds D, Essalmani R, Mayne J, Wickham L, Jin W, Asselin MC, Hamelin J, Varret M, Allard D, Trillard M, Abifadel M, Tebon A, Attie AD, Rader DJ, Boileau C, Brissette L, Chretien M, Prat A, Seidah NG (2004) NARC-1/PCSK9 and its natural mutants: zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol. J Biol Chem 279:48865–44875. doi: 10.1074/jbc.m409699200

4. Benjannet S, Rhainds D, Hamelin J, Nassoury N, Seidah NG (2006) The proprotein convertase (PC) PCSK9 is inactivated by furin and/or PC5/6A: functional consequences of natural mutations and post-translational modifications. J Biol Chem 281:30561–30572. doi: 10.1074/jbc.m606495200

5. Bergeron N, Phan BA, Ding Y, Fong A, Krauss RM (2015) Proprotein convertase subtilisin/kexin type 9 inhibition: a new therapeutic mechanism for reducing cardiovascular disease risk. Circulation 132(17):1648–1666. doi: 10.1161/circulationaha.115.016080

Cited by 48 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. PCSK9 single nucleotide variants might affect susceptibility to malaria through regulation of CD36;Medical Hypotheses;2024-03

2. Role of proprotein convertase subtilisin/kexin type 9 (PCSK9) in diabetic complications;Canadian Journal of Physiology and Pharmacology;2024-01-01

3. Integrated omics approach for the identification of HDL structure-function relationships in PCSK9-related familial hypercholesterolemia;Journal of Clinical Lipidology;2023-09

4. Composition and distribution of lipoproteins after evolocumab in familial dysbetalipoproteinemia: A randomized controlled trial;Journal of Clinical Lipidology;2023-09

5. A Metabolic Enhancer Protects against Diet-Induced Obesity and Liver Steatosis and Corrects a Pro-Atherogenic Serum Profile in Mice;Nutrients;2023-05-22

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3